Difficulty: Medium
Average Score: 83%
Practice
Potency of action of
Correct answer
C
Rationale
The correct answer is C) Miglitol and acarbose are equal in terms of potency of action. This statement is accurate because both miglitol and acarbose are alpha-glucosidase inhibitors used in the management of diabetes mellitus. These medications work by slowing down the digestion and absorption of carbohydrates in the intestines, leading to a decrease in postprandial blood glucose levels.
In terms of potency, clinical studies have shown that there is no significant difference in the efficacy of miglitol compared to acarbose. Both drugs have similar mechanisms of action and are considered to be equally effective in controlling blood sugar levels. Therefore, it is essential for healthcare providers to understand that when choosing between miglitol and acarbose, potency should not be a determining factor.
Regarding why the other options are incorrect:
A) Miglitol is six times higher than that of acarbose - This statement is false as there is no evidence to support that miglitol is six times more potent than acarbose.
B) Acarbose is more than that of miglitol - This option is incorrect as both drugs have comparable potency.
D) Oral hypoglycemic agents depend on the severity of hyperglycemia - While the severity of hyperglycemia may influence the choice of oral hypoglycemic agents, this statement does not directly address the potency of miglitol and acarbose, making it an inaccurate choice in the context of this question.
In an educational context, understanding the potency of different medications used in the management of diabetes is crucial for healthcare providers to make informed decisions regarding treatment options for their patients. By recognizing that miglitol and acarbose have similar potency, clinicians can tailor their therapeutic approach based on other factors such as patient preferences, tolerability, and cost-effectiveness. This knowledge enhances the quality of care provided to individuals with diabetes and helps optimize treatment outcomes.
In terms of potency, clinical studies have shown that there is no significant difference in the efficacy of miglitol compared to acarbose. Both drugs have similar mechanisms of action and are considered to be equally effective in controlling blood sugar levels. Therefore, it is essential for healthcare providers to understand that when choosing between miglitol and acarbose, potency should not be a determining factor.
Regarding why the other options are incorrect:
A) Miglitol is six times higher than that of acarbose - This statement is false as there is no evidence to support that miglitol is six times more potent than acarbose.
B) Acarbose is more than that of miglitol - This option is incorrect as both drugs have comparable potency.
D) Oral hypoglycemic agents depend on the severity of hyperglycemia - While the severity of hyperglycemia may influence the choice of oral hypoglycemic agents, this statement does not directly address the potency of miglitol and acarbose, making it an inaccurate choice in the context of this question.
In an educational context, understanding the potency of different medications used in the management of diabetes is crucial for healthcare providers to make informed decisions regarding treatment options for their patients. By recognizing that miglitol and acarbose have similar potency, clinicians can tailor their therapeutic approach based on other factors such as patient preferences, tolerability, and cost-effectiveness. This knowledge enhances the quality of care provided to individuals with diabetes and helps optimize treatment outcomes.